Search Result

Results for "

humanized

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADAMTS (1) ADC Antibody (26) ADC Cytotoxin (1) Adenylate Cyclase (1) ALCAM/CD166 (1) Amyloid-β (7) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (1) Antibody-Drug Conjugates (ADCs) (14) Apoptosis (21) Autophagy (1) Bacterial (3) c-Fms (5) c-Kit (1) c-Met/HGFR (4) CCR (3) CD19 (4) CD2 (2) CD20 (6) CD22 (4) CD276/B7-H3 (1) CD28 (5) CD3 (12) CD38 (3) CD6 (1) CD73 (3) CD74 (1) CGRP Receptor (3) Checkpoint Kinase (Chk) (1) Complement System (9) CTLA-4 (9) CXCR (3) Drug-Linker Conjugates for ADC (3) EGFR (28) Endothelin Receptor (1) Ephrin Receptor (1) Factor VIII (1) Factor Xa (1) FAP (1) FGFR (2) Filovirus (1) GCGR (1) HBV (1) HIV (5) IFNAR (4) IGF-1R (2) Integrin (12) Interleukin Related (53) LAG-3 (6) Mas-related G-protein-coupled Receptor (MRGPR) (1) Mesothelin (1) Microtubule/Tubulin (5) Monoamine Oxidase (1) Mucin (3) NF-κB (1) Notch (4) P-selectin (2) PD-1/PD-L1 (45) Phosphatase (1) PSMA (1) RABV (1) RSV (4) SARS-CoV (7) Ser/Thr Protease (6) Succinate Receptor 1 (1) TAM Receptor (4) Tau Protein (3) TGF-beta/Smad (2) TGF-β Receptor (1) Thrombin (1) Tie (1) Tim3 (2) TNF Receptor (20) Toll-like Receptor (TLR) (1) Topoisomerase (1) TROP2 (1) VEGFR (15) Wnt (1) α-synuclein (2)
By Research Areas:	Cancer (271) Cardiovascular Disease (21) Endocrinology (1) Infection (30) Inflammation/Immunology (146) Metabolic Disease (16) Neurological Disease (27)

By Targets:

ADAMTS (1)

ADC Antibody (26)

ADC Cytotoxin (1)

Adenylate Cyclase (1)

ALCAM/CD166 (1)

Amyloid-β (7)

Angiotensin-converting Enzyme (ACE) (1)

Antibiotic (1)

Antibody-Drug Conjugates (ADCs) (14)

Apoptosis (21)

Autophagy (1)

Bacterial (3)

c-Fms (5)

c-Kit (1)

c-Met/HGFR (4)

CCR (3)

CD19 (4)

CD2 (2)

CD20 (6)

CD22 (4)

CD276/B7-H3 (1)

CD28 (5)

CD3 (12)

CD38 (3)

CD6 (1)

CD73 (3)

CD74 (1)

CGRP Receptor (3)

Checkpoint Kinase (Chk) (1)

Complement System (9)

CTLA-4 (9)

CXCR (3)

Drug-Linker Conjugates for ADC (3)

EGFR (28)

Endothelin Receptor (1)

Ephrin Receptor (1)

Factor VIII (1)

Factor Xa (1)

FAP (1)

FGFR (2)

Filovirus (1)

GCGR (1)

HBV (1)

HIV (5)

IFNAR (4)

IGF-1R (2)

Integrin (12)

Interleukin Related (53)

LAG-3 (6)

Mas-related G-protein-coupled Receptor (MRGPR) (1)

Mesothelin (1)

Microtubule/Tubulin (5)

Monoamine Oxidase (1)

Mucin (3)

NF-κB (1)

Notch (4)

P-selectin (2)

PD-1/PD-L1 (45)

Phosphatase (1)

PSMA (1)

RABV (1)

RSV (4)

SARS-CoV (7)

Ser/Thr Protease (6)

Succinate Receptor 1 (1)

TAM Receptor (4)

Tau Protein (3)

TGF-beta/Smad (2)

TGF-β Receptor (1)

Thrombin (1)

Tie (1)

Tim3 (2)

TNF Receptor (20)

Toll-like Receptor (TLR) (1)

Topoisomerase (1)

TROP2 (1)

VEGFR (15)

Wnt (1)

α-synuclein (2)

By Research Areas:

Cancer (271)

Cardiovascular Disease (21)

Endocrinology (1)

Infection (30)

Inflammation/Immunology (146)

Metabolic Disease (16)

Neurological Disease (27)

377

Inhibitors & Agonists

465

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99264

Inotuzumab humanized Anti-CD22 Recombinant Antibody	ADC Antibody CD22	Cancer
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .

HY-P99302

Lulizumab humanized Anti-CD28 Recombinant Antibody	CD28	Inflammation/Immunology
Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is a selective CD28 blockade, Lulizumab prevents T cell activation by selectively targeting CD28 signaling .

HY-P99308

Ocaratuzumab AME 133v; LY 2469298; humanized Anti-MS4A1 Recombinant Antibody	CD20	Cancer
Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a K_d of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC) .

HY-P9906A

Bevacizumab (PBS) Maximum Cited Publications 23 Publications Verification Anti-Human VEGF, humanized Antibody (PBS)	VEGFR	Cancer
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity .

HY-P9802

Anti-Spike-RBD Single Domain mAb SARS-CoV-2 (2019-nCoV) Single-Domain Antibodies; humanized Single Domain Antibody	SARS-CoV	Infection
Anti-Spike-RBD Single Domain mAb is a CHO cell derived Alpaca monoclonal VHH-huFc antibody, specifically binds to SARS-CoV-2 RBD with high affinity .

HY-P9914

Eculizumab Anti-Human C5, humanized Antibody	Complement System	Cardiovascular Disease
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab has the potential for haemolysis research .

HY-P9906

Bevacizumab Maximum Cited Publications 23 Publications Verification Anti-Human VEGF, humanized Antibody	VEGFR	Cancer
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.

HY-P9907

Trastuzumab 20+ Cited Publications Anti-Human HER2, humanized Antibody	EGFR ADC Antibody	Cancer
Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

HY-P9917

Tocilizumab 15+ Cited Publications Anti-Human IL6R, humanized Antibody	Interleukin Related	Inflammation/Immunology Cancer
Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis . Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease) .

HY-P9910

Obinutuzumab GA101; Anti-Human CD20 type II, humanized Antibody	CD20	Cancer
Obinutuzumab (GA101) a novel glycoengineered Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.

HY-P9911

Vedolizumab 1 Publications Verification Anti-Human lymphocyte α4β7 integrin, humanized Antibody	Integrin	Inflammation/Immunology Cancer
Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.

HY-P9907A

Trastuzumab (anti-HER2) 20+ Cited Publications Anti-Human HER2, humanized Antibody (PBS)	ADC Antibody EGFR	Cancer
Trastuzumab (PBS) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (PBS) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

HY-P9997

Rosnilimab

ANB030
PD-1/PD-L1 Cancer

Rosnilimab is a humanized IgG1-κ antibody targeting to PD-1 .
HY-P99888

Pimurutamab

EGFR Others

Pimurutamab is a humanized IgG1-κ antibody targeting EGFR. Mainly expressed by CHO-K1 cells .
HY-P99868

Duvortuxizumab

MGD 011
CD19 Others

Duvortuxizumab (MGD 011) is a chimeric humanized IG antibody targeting CD19 and CD3E .
HY-P99118

Serplulimab

HLX 10
PD-1/PD-L1 Cancer

Serplulimab (HLX 10) is humanized monoclonal anti-PD-1 antibody. Serplulimab can be used in research of small cell lung cancer .
HY-P9969

Matuzumab

EMD 72000
EGFR Cancer

Matuzumab (EMD 72000) is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth .

Rosnilimab ANB030	PD-1/PD-L1	Cancer
Rosnilimab is a humanized IgG1-κ antibody targeting to PD-1 .

Pimurutamab	EGFR	Others
Pimurutamab is a humanized IgG1-κ antibody targeting EGFR. Mainly expressed by CHO-K1 cells .

Duvortuxizumab MGD 011	CD19	Others
Duvortuxizumab (MGD 011) is a chimeric humanized IG antibody targeting CD19 and CD3E .

Serplulimab HLX 10	PD-1/PD-L1	Cancer
Serplulimab (HLX 10) is humanized monoclonal anti-PD-1 antibody. Serplulimab can be used in research of small cell lung cancer .

Matuzumab EMD 72000	EGFR	Cancer
Matuzumab (EMD 72000) is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth .

HY-P99210

Olokizumab CDP 6038; OKZ	Interleukin Related	Inflammation/Immunology
Olokizumab (CDP 6038) is a humanized monoclonal antibody targeting the interleukin-6 (IL-6). Olokizumab can be used in research of rheumatoid arthritis (RA) .

HY-P99269

Sibrotuzumab BIBH 1; Anti-Human FAP Recombinant Antibody	FAP	Cancer
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .

HY-P99773

Ongericimab JS002	Ser/Thr Protease	Cardiovascular Disease Metabolic Disease
Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia .

HY-P99854

Disitamab RC48-0	EGFR ADC Antibody	Cancer
Disitamab (RC48-0) is a humanized monoclonal antibody targeting HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (Disitamab vedotin (HY-P9985)) .

HY-P99027

Ieramilimab LAG525; IMP701	LAG-3	Cancer
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules .

HY-P99405

Prasinezumab PRX 002; RG 7935; RO 7046015	α-synuclein	Neurological Disease
Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research .

HY-P99025

Lebrikizumab	Interleukin Related	Inflammation/Immunology
Lebrikizumab is an IgG4 humanized monoclonal antibody that specifically binds to interleukin-13 (IL-13) and inhibits its function. Lebrikizumab can be used for the research of asthma .

HY-P99315

Ruplizumab BG 9588; Anti-Human CD40L Recombinant Antibody	TNF Receptor	Inflammation/Immunology
Ruplizumab (BG 9588) is a humanized monoclonal anti-CD40L (TNF Receptor) IgG1κ antibody. Ruplizumab has the potential for systemic lupus erythematosus disease research .

HY-P99859

Donanemab LY3002813	Amyloid-β	Neurological Disease
Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N‐terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research .

HY-P99010

Bemarituzumab	FGFR	Cancer
Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research .

HY-P99045

Sacituzumab	ADC Antibody	Cancer
Sacituzumab is a humanized IgG1 monoclonal antibody for anti-trophoblast cell-surface antigen 2 (anti-Trop-2). Sacituzumab has the potential for metastatic triple-negative breast cancer research .

HY-P99021

Galcanezumab LY 2951742	CGRP Receptor	Neurological Disease
Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research .

HY-P99015

Dacetuzumab	TNF Receptor	Cancer
Dacetuzumab (SGN-40) is a humanized IgG1, anti-CD40 monoclonal antibody with anti-lymphoma activity. Dacetuzumab kills tumor cells via immune effector functions (antibody-dependent cellular cytotoxicity and phagocytosis [ADCC/ADCP]). Dacetuzumab ((SGN-40) can be used for multiple myeloma research .

HY-P9993

Peresolimab LY-3462817	PD-1/PD-L1	Cancer
Peresolimab is a humanized IgG1-κ antibody targeting to PD-1. Peresolimab potentially stimulates physiological immune inhibitory pathways to restore immune homeostasis .

HY-P99372

Lorvotuzumab Anti-NCAM1/ CD56 Reference Antibody (lorvotuzumab)	ADC Antibody	Cancer
Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine .

HY-P99310

Perakizumab RG4934; Anti-Human IL17A Recombinant Antibody	Interleukin Related	Inflammation/Immunology
Perakizumab (RG4934) is a humanized IgG1κ monoclonal antibody against IL-17A (Interleukin Related). Perakizumab can be uesd for the research of autoimmune diseases, such as psoriatic arthritis .

HY-P99442

Apolizumab Hu1D10	Apoptosis	Inflammation/Immunology
Apolizumab (Hu1D10) is a humanized monoclonal anti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro .

HY-P99106

Acrixolimab

PD-1/PD-L1 Cancer

Acrixolimab a humanized IgG4-κ antibody, targeting to PD-1 .

Acrixolimab	PD-1/PD-L1	Cancer
Acrixolimab a humanized IgG4-κ antibody, targeting to PD-1 .

HY-P99626

Frovocimab LY 3015014	Ser/Thr Protease	Metabolic Disease
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .

HY-P9988

Mecbotamab BA301	ADC Antibody TAM Receptor	Cancer
Mecbotamab is a humanized IgG1-κ antibody targeting to AXL receptor tyrosine kinase (AXL). Mecbotamab can serves as a conditionally active biologic (CAB), which can be conjugated with MMAE (HY-15162) via a cleavable linker, to form ADC Mecbotamab vedotin (BA3011) .

HY-P99019

Fremanezumab TEV-48125	CGRP Receptor	Neurological Disease
Fremanezumab (TEV-48125) is a humanized IgG2a monoclonal antibody that selectively and potently binds to calcitonin gene-related peptide (CGRP). CGRP is a 37-amino acid neuropeptide involved in central and peripheral pathophysiological events of migraine. Fremanezumab has the potential for chronic migraine research .

HY-P99043

Rovalpituzumab	Notch	Cancer
Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine . Rovalpituzumab has activity against small cell lung cancer (SCLC) .

HY-P99313

Quilizumab Anti-Human NGcGM3 Recombinant Antibody	Apoptosis	Inflammation/Immunology
Quilizumab (Anti-Human NGcGM3 Recombinant Antibody) is a humanized IgG1κ monoclonal antibody. Quilizumab targets the M1-prime segment of membrane-expressed IgE, leading to depletion of IgE-switched and memory B cells. Quilizumab has the potantial for the asthma research .

HY-P99153

Farletuzumab MORAb-003	Antibiotic	Cancer
Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer .

HY-147407

Imbotolimod	Others	Cancer
Imbotolimod, immunoglobulin G1-kappa, is a humanized monoclonal antibody with anti-ERBB2 and antineoplastic activity. Imbotolimod is a derivative of telratolimod .

HY-P99044

Sabatolimab MBG453	Tim3	Inflammation/Immunology
Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells .

HY-P99613

Favezelimab MK-4280	LAG-3	Cancer
Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research combined with the PD-L1 inhibitor Pembrolizumab (HY-P9902) .

HY-P99962

Surzebiclimab BGB-A425	Mucin	Cancer
Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody against T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Surzebiclimab binds to the extracellular domain of human Tim-3 with high affinity (K_D=0.36 nM) and specificity. Surzebiclimab can be used in research of cancer .

HY-P99656

Iladatuzumab MCDS0593A	ADC Antibody	Cancer
Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .

HY-P9945

Mepolizumab SB 240563	Interleukin Related	Cardiovascular Disease Inflammation/Immunology
Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .

HY-P9947

Efalizumab	Integrin	Others
Efalizumab is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research .

HY-P9945A

Mepolizumab (anti-IL5)	Interleukin Related	Inflammation/Immunology
Mepolizumab (anti-IL5) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .

HY-P99117

Cadonilimab AK104	PD-1/PD-L1	Cancer
Cadonilimab (AK104) is a targeting PD1/CTLA4 IgG1 scaffold Fc-engineered humanized antibody. Cadonilimab can be used for researching metastatic cervical cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: